BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1384 related articles for article (PubMed ID: 31714636)

  • 1. Lipid lowering and Alzheimer disease risk: A mendelian randomization study.
    Williams DM; Finan C; Schmidt AF; Burgess S; Hingorani AD
    Ann Neurol; 2020 Jan; 87(1):30-39. PubMed ID: 31714636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
    Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
    Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
    Qiao L; Lv S; Meng K; Yang J
    Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
    JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
    Miao L; Miao T; Zhang Y; Hao J
    BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
    JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
    Hong P; Han L; Wan Y
    Eur J Pain; 2024 Jul; 28(6):978-986. PubMed ID: 38183343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
    Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
    Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low LDL cholesterol,
    Benn M; Nordestgaard BG; Frikke-Schmidt R; Tybjærg-Hansen A
    BMJ; 2017 Apr; 357():j1648. PubMed ID: 28438747
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
    Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
    Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK biobank.
    Wang Q; Wang Y; Lehto K; Pedersen NL; Williams DM; Hägg S
    EBioMedicine; 2019 Jul; 45():487-494. PubMed ID: 31300347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
    Lotta LA; Stewart ID; Sharp SJ; Day FR; Burgess S; Luan J; Bowker N; Cai L; Li C; Wittemans LBL; Kerrison ND; Khaw KT; McCarthy MI; O'Rahilly S; Scott RA; Savage DB; Perry JRB; Langenberg C; Wareham NJ
    JAMA Cardiol; 2018 Oct; 3(10):957-966. PubMed ID: 30326043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
    Bi Y; Zhu Y; Tang S; Huang Y
    J Headache Pain; 2023 Aug; 24(1):112. PubMed ID: 37596566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
    Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD
    J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
    Huang W; Xiao J; Ji J; Chen L
    Elife; 2021 Dec; 10():. PubMed ID: 34866576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
    Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.